202 research outputs found
Cancer stem cells in prostate cancer: implications for targeted therapy
Prostate cancer (PCa) is the most frequently diagnosed cancer in men and the second most common cause of cancer-related mortality among men in the developed world. Conventional anti-PCa therapies include surgery, radiation, hormonal ablation, and chemotherapy. Despite increasing efforts, these therapies are not effective for patients with advanced and/or metastatic disease. In most cases, cancer therapies fail due to an incomplete depletion of tumor cells, resulting in tumor relapse. The cancer stem cell (CSC) hypothesis is an emerging model that explains many of the molecular characteristics of oncological disease as well as the tendency of cancers to relapse, metastasize, and develop resistance to conventional therapies. CSCs are a reservoir of cancer cells that exhibit properties of self-renewal and the ability to reestablish the heterogeneous tumor cell population. The existence of PCa stem cells offers a theoretical explanation for many uncertainties regarding PCa and also for treatment resistance and disease progression once clinical cure is achieved. Therapies targeting CSCs might therefore lead to more effective cancer treatments, divergent from a traditional anti-proliferative approach, based on tumor bulk reduction accompanied by CSC-specific inhibition. Here, we focus on reviewing the historical perspective as well as concepts regarding stem cells and CSCs in PCa. In addition, we will report possible strategies and new clinical approaches that address the CSC-based concept of tumorigenesis in PCa. (C) 2017 S. Karger AG, Base
When Parallel Roads Meet: Orchestrating Collaborations Between Regulatory, Ethical, and Business Partners in Translational Medicine
When Parallel Roads Meet: Orchestrating Collaborations Between Regulatory, Ethical, and Business Partners in Translational Medicine
Oncologic surveillance for subjects with biallelic mismatch repair gene mutations-10 year follow-up in a kindred
Improving Deep Learning Models for Pediatric Low-Grade Glioma Tumors Molecular Subtype Identification Using 3D Probability Distributions of Tumor Location
Background and Purpose: Pediatric low-grade glioma (pLGG) is the most common
type of brain tumor in children, and identification of molecular markers for
pLGG is crucial for successful treatment planning. Convolutional Neural Network
(CNN) models for pLGG subtype identification rely on tumor segmentation. We
hypothesize tumor segmentations are suboptimal and thus, we propose to augment
the CNN models using tumor location probability in MRI data.
Materials and Methods: Our REB-approved retrospective study included MRI
Fluid-Attenuated Inversion Recovery (FLAIR) sequences of 143 BRAF fused and 71
BRAF V600E mutated tumors. Tumor segmentations (regions of interest (ROIs))
were provided by a pediatric neuroradiology fellow and verified by a senior
pediatric neuroradiologist. In each experiment, we randomly split the data into
development and test with an 80/20 ratio. We combined the 3D binary ROI masks
for each class in the development dataset to derive the probability density
functions (PDF) of tumor location, and developed three pipelines:
location-based, CNN-based, and hybrid.
Results: We repeated the experiment with different model initializations and
data splits 100 times and calculated the Area Under Receiver Operating
Characteristic Curve (AUC). The location-based classifier achieved an AUC of
77.90, 95% confidence interval (CI) (76.76, 79.03). CNN-based classifiers
achieved AUC of 86.11, CI (84.96, 87.25), while the tumor-location-guided CNNs
outperformed the formers with an average AUC of 88.64 CI (87.57, 89.72), which
was statistically significant (Student's t-test p-value 0.0018).
Conclusion: We achieved statistically significant improvements by
incorporating tumor location into the CNN models. Our results suggest that
manually segmented ROIs may not be optimal.Comment: arXiv admin note: text overlap with arXiv:2207.1477
DNA methylation signature is prognostic of choroid plexus tumor aggressiveness
Abstract: Background: Histological grading of choroid plexus tumors (CPTs) remains the best prognostic tool to distinguish between aggressive choroid plexus carcinoma (CPC) and the more benign choroid plexus papilloma (CPP) or atypical choroid plexus papilloma (aCPP); however, these distinctions can be challenging. Standard treatment of CPC is very aggressive and often leads to severe damage to the young child’s brain. Therefore, it is crucial to distinguish between CPC and less aggressive entities (CPP or aCPP) to avoid unnecessary exposure of the young patient to neurotoxic therapy. To better stratify CPTs, we utilized DNA methylation (DNAm) to identify prognostic epigenetic biomarkers for CPCs. Methods: We obtained DNA methylation profiles of 34 CPTs using the HumanMethylation450 BeadChip from Illumina, and the data was analyzed using the Illumina Genome Studio analysis software. Validation of differentially methylated CpG sites chosen as biomarkers was performed using pyrosequencing analysis on additional 22 CPTs. Sensitivity testing of the CPC DNAm signature was performed on a replication cohort of 61 CPT tumors obtained from Neuropathology, University Hospital Münster, Germany. Results: Generated genome-wide DNAm profiles of CPTs showed significant differences in DNAm between CPCs and the CPPs or aCPPs. The prediction of clinical outcome could be improved by combining the DNAm profile with the mutational status of TP53. CPCs with homozygous TP53 mutations clustered as a group separate from those carrying a heterozygous TP53 mutation or CPCs with wild type TP53 (TP53-wt) and showed the worst survival outcome. Specific DNAm signatures for CPCs revealed AK1, PER2, and PLSCR4 as potential biomarkers for CPC that can be used to improve molecular stratification for diagnosis and treatment. Conclusions: We demonstrate that combining specific DNAm signature for CPCs with histological approaches better differentiate aggressive tumors from those that are not life threatening. These findings have important implications for future prognostic risk prediction in clinical disease management
THOR is a targetable epigenetic biomarker with clinical implications in breast cancer
Breast cancer (BC) is the most frequently diagnosed cancer and a leading cause of death among
women worldwide. Early BC is potentially curable, but the mortality rates still observed among BC patients demon‑
strate the urgent need of novel and more efective diagnostic and therapeutic options. Limitless self-renewal is a
hallmark of cancer, governed by telomere maintenance. In around 95% of BC cases, this process is achieved by telom‑
erase reactivation through upregulation of the human telomerase reverse transcriptase (hTERT). The hypermethylation
of a specifc region within the hTERT promoter, termed TERT hypermethylated oncological region (THOR) has been
associated with increased hTERT expression in cancer. However, its biological role and clinical potential in BC have
never been studied to the best of our knowledge. Therefore, we aimed to investigate the role of THOR as a biomarker
and explore the functional impact of THOR methylation status in hTERT upregulation in BC.info:eu-repo/semantics/publishedVersio
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells
Pediatric ependymomas are highly recurrent tumors resistant to conventional chemotherapy. Telomerase, a ribonucleoprotein critical in permitting limitless replication, has been found to be critically important for the maintenance of tumor-initiating cells (TICs). These TICs are chemoresistant, repopulate the tumor from which they are identified, and are drivers of recurrence in numerous cancers. In this study, telomerase enzymatic activity was directly measured and inhibited to assess the therapeutic potential of targeting telomerase. Telomerase repeat amplification protocol (TRAP) (n = 36) and C-circle assay/telomere FISH/ATRX staining (n = 76) were performed on primary ependymomas to determine the prevalence and prognostic potential of telomerase activity or alternative lengthening of telomeres (ALT) as telomere maintenance mechanisms, respectively. Imetelstat, a phase 2 telomerase inhibitor, was used to elucidate the effect of telomerase inhibition on proliferation and tumorigenicity in established cell lines (BXD-1425EPN, R254), a primary TIC line (E520) and xenograft models of pediatric ependymoma. Over 60 % of pediatric ependymomas were found to rely on telomerase activity to maintain telomeres, while no ependymomas showed evidence of ALT. Children with telomerase-active tumors had reduced 5-year progression-free survival (29 +/- A 11 vs 64 +/- A 18 %; p = 0.03) and overall survival (58 +/- A 12 vs 83 +/- A 15 %; p = 0.05) rates compared to those with tumors lacking telomerase activity. Imetelstat inhibited proliferation and self-renewal by shortening telomeres and inducing senescence in vitro. In vivo, Imetelstat significantly reduced subcutaneous xenograft growth by 40 % (p = 0.03) and completely abolished the tumorigenicity of pediatric ependymoma TICs in an orthotopic xenograft model. Telomerase inhibition represents a promising therapeutic approach for telomerase-active pediatric ependymomas found to characterize high-risk ependymomas.Canadian Institutes of Health Research [MOP 82727]info:eu-repo/semantics/publishedVersio
The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants
Multiple independent genomic profiling efforts have recently identified clinically and molecularly distinct subgroups of ependymoma arising from all three anatomic compartments of the central nervous system (supratentorial brain, posterior fossa, and spinal cord). These advances motivated a consensus meeting to discuss: (1) the utility of current histologic grading criteria, (2) the integration of molecular-based stratification schemes in future clinical trials for patients with ependymoma and (3) current therapy in the context of molecular subgroups. Discussion at the meeting generated a series of consensus statements and recommendations from the attendees, which comment on the prognostic evaluation and treatment decisions of patients with intracranial ependymoma (WHO Grade II/III) based on the knowledge of its molecular subgroups. The major consensus among attendees was reached that treatment decisions for ependymoma (outside of clinical trials) should not be based on grading (II vs III). Supratentorial and posterior fossa ependymomas are distinct diseases, although the impact on therapy is still evolving. Molecular subgrouping should be part of all clinical trials henceforth
Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma
Despite the histological similarity of ependymomas from throughout the neuroaxis, the disease likely comprises multiple independent entities, each with a distinct molecular pathogenesis. Transcriptional profiling of two large independent cohorts of ependymoma reveals the existence of two demographically, transcriptionally, genetically, and clinically distinct groups of posterior fossa (PF) ependymomas. Group A patients are younger, have laterally located tumors with a balanced genome, and are much more likely to exhibit recurrence, metastasis at recurrence, and death compared with Group B patients. Identification and optimization of immunohistochemical (IHC) markers for PF ependymoma subgroups allowed validation of our findings on a third independent cohort, using a human ependymoma tissue microarray, and provides a tool for prospective prognostication and stratification of PF ependymoma patients
- …